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Abstract: Background: Coronary artery revascularisation procedures (CARPs) include coronary artery bypass graft pro-
cedures (CABGs) and the less invasive percutaneous coronary interventions (PCIs) and they are common surgical inter-
ventions for coronary heart disease (CHD). The effectiveness of PCIs increased when stents were introduced and there 
was also a shift towards doing more PCIs and less CABGs, especially in older patients. More recently, PCIs have been 
further improved by the use of drug-eluting-stents (DES). In this study we used a recently developed CHD/CARP Markov 
model to explore the likely effect on CARP requirements due to the introduction of DES. 
Methods: This is achieved by considering the population of Western Australia aged 35 to 79 years at the beginning of 
2001 (grouped according to history of CHD and CARPs) as the cohort, calculating the mean population risks for 
CHD/CARP events over three years 1998 to 2000, and using these population risks and certain modifications of them that 
incorporate the likely effect of the introduction of DES (in 2002) in the CHD/CARP Markov model to explore difference 
in total requirements for CABGs and PCIs over the period 2001 to 2010. The anticipated likely effect of DES on prob-
abilities of CARP procedures was based on results of meta-analysis of randomized controlled trials comparing DES stents 
to ordinary stents and an anticipated further reduction in CABGs and increase in PCIs as was observed when (ordinary) 
stents were introduced. 
Results: The simulation results suggest that, over the period 2001 to 2010, the total number of CABGs will decline by up 
to 19% and the total number of PCIs will increase by up to 6%. 
Conclusion: The introduction of DES will have greater effect on the requirement of CABGs as compared to that on PCIs. 
INTRODUCTION 
 Although rates of coronary heart disease (CHD) have 
been declining for 20 years it still remains a major cause of 
morbidity and mortality [1]. Surgical interventions for CHD 
include coronary artery bypass graft procedures (CABGs) 
and the less invasive percutaneous coronary interventions 
(PCIs) and together these are known as coronary artery re-
vascularisation procedures (CARPs). The effectiveness and 
scope of PCI procedures increased, first with the develop-
ment of balloon angioplasty, then with the insertion of stents 
to keep the coronary arteries open, and more recently with 
the use of drug-eluting stents (DES). Meta-analyses of ran-
domized controlled trials [2] and population based observa-
tional studies [3] have already shown that ordinary stents 
have contributed to a decline in the risk of a repeat CARP. 
More recent meta-analyses of randomized controlled trials 
comparing drug-eluting to ordinary stents [4-7] suggest even 
greater effectiveness. Moreover, a population based model-
ing approach has suggested that DES will lead to a further 
reduction in the need for revision procedures [3]. 
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 In Australia, CARPs are common as illustrated by age-
standardised rates for PCI and CABG of 1,022 and 809 per 
million population in the year 2000 [8]. The state of Western 
Australia has seen very rapid uptake of PCI technology, with 
PCIs making up 64 percent of all CARPs during 2000-2001 
[9]. Ordinary stents were introduced into PCI procedures in 
1995 with 90.7% of PCI procedures using stents by 2000-
2001. DES were introduced in 2002 and by 2005 about 90% 
of PCIs performed in Western Australia were using DES 
[10]. The uptake however has not been as rapid in other 
states of Australia [11, 12]. 
 The introduction of stents had two principal effects on 
CARP requirements. First, it reduced the risk of a repeat 
CARP following a primary PCI and second, it initiated a 
shift towards doing less CABGs and more PCIs. Random-
ised control trial evidence indicates that the introduction of 
DES will reduce the risk of a repeat CARP following pri-
mary PCI even further [6, 7] but it is unclear if it will initiate 
a further shift from CABG to PCI overall. 
 In view of the rapid uptake of DES and the uncertainty 
about what the effect of DES might be on the requirements 
of CARPs, we have used a recently developed CHD/CARP 
Markov simulation model [13-15] to explore the likely ef-
fects of DES on future requirements for CARPs in the West-
ern Australian population. 
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METHODS 
 Models: The CHD/CARP Markov simulation model has 
been described in detail previously [13-15]. Briefly, the 
model is based on annual risks, stratified by age, gender and 
CHD/CARP history, for admission to hospital for CHD, for 
a PCI, for a CABG, for CHD death and non-CHD death. 
Each member of a population cohort is placed in one of sev-
eral mutually exclusive CHD/CARP history states based on 
their hospital admissions history for the period 1980 to 2000: 
[1] a history of having a PCI but no CABG some time in the 
past; [2] a history of having a CABG some time in the past; 
[3] a history of having a CHD admission but no CABG or 
PCI some time in the past; or [4] no history of CHD admis-
sion, CABG and PCI in the past. The model allows members 
to move from one state to another in each cycle (year) ac-
cording to the events they experience during the year. Within 
a cycle, the model allows for a CHD admission without a 
CARP, up to two admissions with CARPs (CABG or PCI) in 
addition to possible death. The schematic diagram for the 
model is shown in Fig. (1). 
 Data: The model is applied to the cohort comprising the 
population of the state of Western Australia aged 35 to 79 
years at the beginning of 2001. Using linked records for in-
dividuals in the WA Health Linked Data system [16] to-
gether with population census data, each member of the 
Western Australian population cohort is placed in one of the 
four hospital admissions history states. 
 Analysis: The model incorporates ageing of cohort mem-
bers and requires values of event risks for each age, gender 
and history state for each year in order for the events for the 
cohort to be simulated. In the context of forecasting, popula-
tion event risks for past years (1998 to 2000 in our case) are 
calculated and used to project event risks for future years. 
The validation of the model and a demonstration of its use 
for forecasting (from 1995 to 1999) have been described and 
discussed previously [13-15]. 
 
 To simulate the numbers of CABGs and PCIs for the 
2001 WA population cohort over the period 2001 to 2010, 
the average population event risks for 1998 to 2000 are used 
for each year from 2001 to 2010. To assess the likely effect 
of the introduction of stents in 2002, some of the CARP 
event risks are altered for the years 2002 to 2010. The results 
reported in this paper are based on the assumption that all 
patients undergoing a PCI in 2002 and onwards receive a 
DES. This is reasonable considering that, in Western Austra-
lia, about 90 percent of all patients undergoing a PCI have 
been getting a DES since its introduction [10]. 
 Two types of event risks are altered due to the introduc-
tion of DES. First, the risks of a second PCI and/or CABG in 
the same year following a primary PCI are altered to reflect 
the increased effectiveness of DES over ordinary stents. 
These repeat CARP risks were observed to decline after the 
introduction of ordinary stents in 1995 and the relative risk 
reduction at the population level which resulted from the 
introduction of ordinary stents in 1995 was similar to that 
found in meta-analyses of randomized controlled trials [9, 
14]. This is the basis for altering these same event risks fol-
lowing introduction of DES. The evidence from several 
meta-analyses of randomized controlled trials that compare 
DES to ordinary stents is that the use of DES will reduce the 
risk of restenosis and CABG by about 40% [4-6] while an-
other meta-analysis has shown DESs to reduce the risk of 
repeat PCI by about 79 percent and CABG by 69 percent [7]. 
In our simulation we have used a risk reduction for repeat 
CARP (when the first CARP is PCI) of 50%. 
 The second type of event risk that was altered was the 
overall risk of a PCI and a CABG. It was observed that for 
the period 1995-99 the risk of a PCI increased while the risk 
of a CABG declined after the introduction of ordinary stents 
in 1995 [14, 15]. Thus, we consider another scenario that the 
introduction of DES will result in a further increase in the 
risk a PCI and a decrease in the risk of a CABG. These 
changes in risk are expected to capture a further shift  
 
 
Fig. (1). Schematic diagram for the recognised events during a cycle (year). 
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towards more PCIs and less CABGs. The risk changes fol-
lowing introduction of stents in 1995 was a 25% increase in 
PCI and a 15% decrease in risk of CABG for males and a 
12.5% increase in risk of PCI and 7.5% decrease in risk of 
CABG for females. Based on these values and expert opin-
ion we assume that the effect of introduction of DES will be 
to increase risk of PCI by 10% and reduce the risk of CABG 
by 10%. 
 Three simulations are conducted [1] using the average 
events risks from 1998-2000 for all event risks [2] using the 
average event risks from 1998-2000 for all events except the 
risk for repeat CARPs when the primary CARP is PCI which 
are modified as described above, and [3] using the average 
event risks from 1998-2000 for all events except for the risk 
of repeat CARPs when the primary CARP is PCI and the 
overall risk of CABG and PCI which are modified as de-
scribed above. These three simulation scenarios are called 
Mean, DES [1] and DES [2] respectively. 
RESULTS 
 Table 1 shows the total simulated number of CABGs and 
PCIs over the period 2001-2010 under the three sets of event 
risk described in Methods for the population of Western 
Australia aged 35-79 years in 2001 (n=8, 97, 477). In com-
parison to the Mean method, the total number of CABGs 
decreased by 7.4 percent under DES [1] and by 19.2 percent 
under DES(2). The total number of PCIs decreased by 3.4 
percent under DES [1] and increased by 6.3 percent under 
DES [2]. 
 Since the effect of DES on future numbers of CARPs 
may take a few years to emerge, it is important to look at 
predicted event numbers by each calendar year. Fig. (2) 
shows the total projected numbers of CABGs and PCIs ob-
tained under the three scenarios by single year over 2001-
2010. This figure shows that differences increase slowly 
each year from 2003. 
 
Table 1. Comparison between Projected Numbers of CARPs 
(2001-2010) Based on Mean, DES(1) and DES(2) 
Scenarios for Western Australia Population 35-79 
Years in 2001 
 
Scenario Total CABGs 2001-2010 Total PCIs 2001-2010 
Mean 15,752 24,474 
DES(1) 14,588 (-7.4%) 23,631 (-3.4%) 
DES(2) 12,728 (-19.2%) 26,025 (+6.3%) 
 
DISCUSSION 
 The forecasts regarding future requirements for CABGs 
and PCIs as performed in this study were based on reasona-
bly conservative estimates of the effect of DES on repeat 
procedures and the shift from CABGs to PCIs. The modeling 
of 10 percent magnitude of change in the risk of a CABG 
and that of a PCI for the final DES scenario deserves some 
explanation. Based on expert opinion we assumed that the 
magnitude of these changes were not as pronounced when 
DES was introduced compared to ordinary stent. The magni-
tude of 10 percent change in the relevant risks since 2002 is 
almost half the change in these risks which occurred after 
ordinary stents were introduced in WA in 1995 [9] and hence 
we believe that the scenario we developed was fairly reason-
able. We simulated another DES scenario with a magnitude 
of 20 percent change in the relevant risks and also found that 
the introduction of DES will result in a smaller increase in 
the requirements for PCIs but a larger decrease in the re-
quirements for CABGs (data not given). 
 Thus, all the forecasts regarding future trends for CABGs 
and PCIs as performed in this study are expected to be rea-
sonable as we believe that we did not seriously over- or un-
der- estimate the magnitude of the changes in the transition  
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Fig. (2). Comparison between total projected numbers of CABGs and PCIs each year under mean, DES(1) and DES(2) scenarios over the 
period 2001-2010. 
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probabilities at the population level based on results from 
meta-analyses of RCTs and was able to foresee major future 
changes in the model’s parameters due to advancement in 
PCIs. Thus, these forecasts represent our best projections 
based on the premise that the events of the recent past can be 
used as a guide to the future. 
 The single year projections showed that the effect of DES 
on the requirements for CARPs gradually increases with 
time. When the increased effectiveness of PCI due to an in-
troduction of DES was captured by reducing the risks of a 
repeat PCI (DES [1]), there was a small decline in the re-
quirements for PCIs with the effect having a lag and a larger 
decline in the requirements for CABGs. When further 
changes were incorporated that captured a shift in practice 
between a CABG and a PCI (DES [2]) there was a small 
increase in the requirements for PCIs with a lag in the effect 
but a substantial decrease in the requirements for CABGs. 
 For simplicity, we have incorporated the effect of DESs 
into the projected risks by a constant relative risk reduction 
for the specified events. However, whilst this is reasonable 
for Western Australia where the uptake is very rapid [10], 
the uptake of DES in other populations may be more grad-
ual. The CHD/CARP simulation model is flexible enough to 
model this. Also, for simplicity we have assumed that the 
decline in these risks is uniform across both sexes and all age 
groups. It is possible that the DES effect may vary by age 
and sex. We did not however find any evidence in support of 
this as no meta-analysis has examined the effect of DES on 
these outcomes in different age-sex subgroups of patients. 
 In Australia, the cost of DESs is about three to four times 
that of ordinary stents [12]. As a result, DES use in the pub-
lic health system (except in WA) is reserved for selected 
cases (eg, for patients at high risk of restenosis) [12]. How-
ever, unrestricted DES use as in WA may not be economi-
cally viable under the public health system. A recent cost-
effectiveness analysis in the US suggested the sirolimus-
eluting stent would be a cost effective treatment strategy 
when the rate of restenosis exceeds 18.5% [17]. A recent 
Australian study showed that limiting DES use to patients at 
the highest risk of restenosis might improve the cost-
effectiveness of DESs in an Australian model based on ran-
domised trial results [6]. 
 The CHD/CARP model can also be used to determine the 
effect on requirements of CARPs of advances in medical 
treatments related to CHD, changes in trends of CHD inci-
dence stemming from changes in risk factor trends (eg, the 
obesity epidemic) and changes in health policy related to 
treating CHD patients. Examples of determining effects of 
advances in medical treatments include increasing use of 
prescribed aspirin, lipid lowering drugs, statins and ACE 
inhibitors. Examples of examining effects on requirements of 
CARPs due to changes in health policy include change in 
health policy (by the Australian government) regarding sub-
sidising statins by only providing subsidy to people at higher 
risk of CHD. In terms of the CHD/CARP model, this can be 
explored by altering incidence transition probabilities to take 
into consideration more restricted access to subsidized stat-
ins. The CHD/CARP model can further be used to determine  
 
 
the cost of future requirements for CARPs and to explore the 
most cost-effective strategies for treatment of CHD. To 
achieve this indicative cost estimates are needed for each of 
the alternative CARP treatments including CABG and PCI 
with ordinary stent and DES. Such cost data on alternative 
CARP treatments may be obtained from information from 
the patient costing databases at the WA teaching hospitals. 
Future cost estimates may be obtained by time series model-
ling using information relating to variables such as Com-
monwealth Medicare Benefit Schedule (CMBS) rates, Diag-
nosis Related Group (DRG) costs, procedure-specific costs, 
theatre time and lengths of hospital stay. Expert advice re-
garding costs can also be obtained from clinicians and hospi-
tal finance personnel. 
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